APUS - Apimeds Pharmaceuticals US, Inc.
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 2.39 -0.01 (-0.42%) | --- | 0.06 (2.59%) | -0.04 (-1.65%) | --- | -0.01 (-0.42%) | --- | --- |
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Market
Earnings & Ratios
- Basic EPS:
- -0.26
- Diluted EPS:
- -0.26
- Basic P/E:
- -9.1538
- Diluted P/E:
- -9.1538
- RSI(14) 1m:
- 0.0
- VWAP:
- 2.36
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|